Device designed to treat a leading cause of blindness

February 29, 2012 By Alexis Blue, University of Arizona
Device designed to treat a leading cause of blindness
A new investigational device, invented by a UA professor, could dramatically change the way the degenerative disease is treated.

(Medical Xpress) -- Every year, more than 200,000 people in the U.S. are diagnosed with Wet Age-Related Macular Degeneration, a leading cause of blindness in Americans age 60 or older. There is no known cure for the disease, which can lead to partial or complete vision loss.

But a new investigational device, invented by a University of Arizona professor, could dramatically change the way the is treated.

Wet Age-Related , or Wet AMD, occurs when begin to grow behind the eye's macula, located in the center of the retina, and leak fluid that causes the macula to shift from its normal position and become damaged. It is more serious than the more common Dry , which occurs when in the macula break down, blurring .

One of the most common treatments for Wet AMD is repeated injections into the eye of anti-VGEF (anti-Vascular Endothelial Growth Factor) drugs, designed to slow the growth of abnormal .

But those injections, administered as often as once a month for life, can be uncomfortable for patients and are not effective for everyone, said Russell Hamilton, professor and head of the physics section of the UA department of oncology.

So Hamilton set out to find a less invasive way to treat patients that would reduce, or perhaps altogether eliminate, the need for repeated anti-VGEF injections.

His investigational device, which is now in the early stages of human study, is designed to deliver targeted radiation to blood vessel leaks via a small radioactive seed inserted behind the eye. The idea is that targeted radiation will provide a more long-term solution and help increase the effectiveness of initial anti-VGEF injections.

"When you're diagnosed with Wet AMD, you would have the anti-VGEF injection immediately. We're hoping the radiation will then increase the durability of the treatment, so that after the first month patients won't need to be injected again," said Hamilton, who also is a co-founder of Salutaris Medical Devices Inc., a privately held Tucson company founded to develop an investigational ophthalmic treatment for Wet AMD.

The device, about six inches in length, includes a wire with a curved end, designed to fit around the eye. It is inserted over the top of the eye, through a small incision, and moved toward the back of the eye, where it delivers a dose of radiation to repair troublesome leaks.

Requiring only a small incision, the procedure is minimally invasive and is intended to be done under local anesthesia in approximately 15 minutes in a physician's office or outpatient setting.

Researchers say it could be a safer, simpler alternative to external radiation, which also has been used to treat Wet AMD, and to other investigational treatments that involve penetration of the eye to deliver radiation.

"If this is proven in a larger trial, it's going to be game changing," said Dr. Baldassarre Stea, professor and chairman of the UA department of radiation oncology and co-principal investigator of the device study, along with Dr. Reid Schindler, clinical associate professor in the UA department of ophthalmology and vision science.   

"Not only is it going to be beneficial from an economic point of view, in an era where resources are limited and the injections cost $2,000 a shot, but the quality of life of the patient will also be impacted," Stea said. "You regain your vision better, you don't have to go back and forth to the ophthalmologist every month to get the injection, and you save money and aggravation."

Hamilton said he began working on his device after learning of the successful use of radiation to treat melanoma of the eye.

In January, the results of a Phase 1 study to evaluate the safety of the device were shared during Meeting 2012. Of the six test subjects treated with the device, all saw improvement in vision, none experienced additional and three were able to discontinue their anti-VGEF injections. Furthermore, there were no reported "Serious Adverse Events" or "Unanticipated Adverse Device Effects."

Additional studies are expected to get under way later this year. Stea said if those go well, FDA approval for the device could happen within a few years.

Explore further: Vision loss slowed by encapsulated cell therapy

Related Stories

Vision loss slowed by encapsulated cell therapy

April 7, 2011
( -- A phase 2 clinical trial for the treatment of a severe form of age-related macular degeneration called geographic atrophy (GA) has become the first study to show the benefit of a therapy to slow the progression ...

Report shows risk of blindness halved over last decade

January 19, 2012
Age-related macular degeneration (AMD) is the most frequent cause of blindness in the Western World. A report from the University of Copenhagen and Glostrup Hospital in Denmark published today shows the number of new cases ...

Study shows daily aspirin intake can lead to blindness

October 5, 2011
(Medical Xpress) -- A new study published in Ophthalmology reveals that while taking a daily aspirin may reduce the risks of heart disease and stroke, a disturbing side effect has also been noted to increase the risk of developing ...

Recommended for you

Study advances gene therapy for glaucoma

January 16, 2018
While testing genes to treat glaucoma by reducing pressure inside the eye, University of Wisconsin-Madison scientists stumbled onto a problem: They had trouble getting efficient gene delivery to the cells that act like drains ...

New study offers added hope for patients awaiting corneal transplants

January 9, 2018
New national research led by Jonathan Lass of Case Western Reserve University School of Medicine has found that corneal donor tissue can be safely stored for 11 days before transplantation surgery to correct eye problems ...

Diabetic blindness caused and reversed "trapped" immune cells in rodent retinas

January 3, 2018
Johns Hopkins researchers have discovered a cell signaling pathway in mice that triggers vision loss in patients with diabetic retinopathy and retinal vein occlusion – diseases characterized by the closure of blood vessels ...

Ophthalmologists increasingly dissatisfied with electronic health records

December 29, 2017
Ophthalmologists' use of electronic health records (EHR) systems for storing and accessing patients' medical histories more than doubled between 2006 and 2016, while their perceptions of financial and clinical productivity ...

Higher omega-3 fatty acid intake tied to lower glaucoma risk

December 26, 2017
(HealthDay)—Increased daily intake of ω-3 fatty acids is associated with lower odds of glaucoma, but higher levels of total polyunsaturated fatty acid (PUFA) intake are associated with higher odds of developing glaucoma, ...

Protein analysis allows for treatment of eye-disease symptoms with existing drugs

December 21, 2017
Demonstrating the potential of precision health, a team led by a researcher at the Stanford University School of Medicine has matched existing drugs to errant proteins expressed by patients with a rare eye disease.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.